# Plain Language Summary: World Sickle Cell Awareness Day Resolution

This resolution is Congress's way of officially recognizing June 19, 2025, as "World Sickle Cell Awareness Day" across the United States and internationally. It's essentially a symbolic statement expressing support for bringing attention to sickle cell disease, a serious inherited blood disorder that affects thousands of Americans, particularly people of African descent.

The resolution highlights several important goals related to sickle cell disease: increasing public awareness about the condition, supporting continued research to find better treatments and eventually a cure, promoting early detection through screening programs, and developing better ways to prevent complications from the disease. Sickle cell disease causes severe pain, organ damage, and shortened lifespans for those who have it, so the resolution emphasizes the need for better medical solutions and preventative care.

In practical terms, this resolution doesn't create new laws or funding programs—it's not the type of bill that directly changes what people can do or receive. Instead, it's a formal acknowledgment from Congress that sickle cell disease deserves more attention and resources. By designating a specific awareness day, Congress is encouraging healthcare providers, researchers, patient advocacy groups, and the general public to focus on this disease and the people living with it. For patients and families affected by sickle cell disease, this kind of official recognition can help bring visibility to their struggles and potentially influence future policy decisions and funding priorities related to research and treatment.

A resolution expressing support for the designation of June 19, 2025, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.